Alpha 2.0
Login Register
» Journals » Blood Cancer J

Blood Cancer Journal

Blood Cancer Journal is a peer-reviewed open-access journal that focuses on all aspects of hematological malignancies. It publishes high-quality research articles, reviews, and case reports, providing a platform for the dissemination of cutting-edge knowledge in the field. With a multidisciplinary approach, the journal aims to advance understanding, diagnosis, and treatment of blood cancers, fostering collaboration among researchers, clinicians, and scientists worldwide.
Details
Abbr. Blood Cancer J
Start 2011
End Continuing
Frequency Irregular
e-ISSN 2044-5385
Country United States
Language English
Metrics
h-index / Ranks: 4647 76
SJR / Ranks: 375 3974
CiteScore / Ranks: 763 13.40
JIF / Ranks: 296 12.8
Recent Articles
1.
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study
Jiang B, Tong H, Meng H, Xie W, Yu W, Huang J, et al.
Blood Cancer J . 2025 Mar; 15(1):39. PMID: 40089468
No abstract available.
2.
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
Soureas K, Malandrakis P, Papadimitriou M, Minopoulos C, Ntanasis-Stathopoulos I, Liacos C, et al.
Blood Cancer J . 2025 Mar; 15(1):41. PMID: 40089465
The persistence of high relapse rates and therapy resistance continues to challenge the effective management of multiple myeloma (MM). The identification of novel MM-specific molecular markers could ameliorate risk-stratification tools...
3.
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Fiskus W, Mill C, Piel J, Collins M, Hentemann M, Cuglievan B, et al.
Blood Cancer J . 2025 Mar; 15(1):40. PMID: 40089460
Although treatment with standard frontline therapies, including a FLT3 inhibitor (FLT3i) reduces AML burden and achieves clinical remissions, most patients with AML with FLT3 mutation relapse due to therapy-resistant stem/progenitor...
4.
Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortium
Rajendra A, Sengar M, Korula A, Ganesan P, Jain H, K D, et al.
Blood Cancer J . 2025 Mar; 15(1):38. PMID: 40087298
Treatment of Burkitt Lymphoma/Leukemia (BL/L) in adults has evolved from the use of pediatric inspired regimens (CODOX-M/IVAC, hyper-CVAD, GMALL) to the use of lower intensity EPOCH regimens. The addition of...
5.
Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
Souto Filho J, Cantadori L, Crusoe E, Hungria V, Maiolino A
Blood Cancer J . 2025 Mar; 15(1):37. PMID: 40082415
The treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (TE-NDMM) has evolved with the introduction of daratumumab-based quadruplet regimens. Adding daratumumab to traditional triplet regimens has demonstrated improved...
6.
Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
Luchinin A, Gevorkyan T, Semenova A
Blood Cancer J . 2025 Mar; 15(1):36. PMID: 40082408
No abstract available.
7.
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study
Busque L, Beaudet M, Harnois M, Moussa H, Szuber N, Mollica L, et al.
Blood Cancer J . 2025 Mar; 15(1):35. PMID: 40069191
No abstract available.
8.
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
Dileo R, Mewawalla P, Babu K, Yin Y, Strouse C, Chen E, et al.
Blood Cancer J . 2025 Mar; 15(1):34. PMID: 40064854
While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple...
9.
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope
Argnani L, Casadei B, Zinzani P
Blood Cancer J . 2025 Mar; 15(1):33. PMID: 40055342
No abstract available.
10.
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
Davis J, Snyder J, Rice M, Moore D, Cahoon C, Julian K, et al.
Blood Cancer J . 2025 Mar; 15(1):32. PMID: 40038247
No abstract available.